DekaBank Deutsche Girozentrale Has $22.39 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

DekaBank Deutsche Girozentrale cut its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 93,165 shares of the biotechnology company’s stock after selling 1,478 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in United Therapeutics were worth $22,392,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Cetera Advisors LLC acquired a new stake in shares of United Therapeutics during the 1st quarter worth $475,000. Burney Co. lifted its position in shares of United Therapeutics by 119.1% during the 1st quarter. Burney Co. now owns 22,449 shares of the biotechnology company’s stock worth $5,157,000 after buying an additional 12,205 shares during the last quarter. Beck Bode LLC bought a new stake in shares of United Therapeutics during the 1st quarter worth $1,839,000. Swedbank AB bought a new stake in shares of United Therapeutics during the 1st quarter worth $97,316,000. Finally, Delphi Management Inc. MA bought a new stake in shares of United Therapeutics during the 1st quarter worth $1,357,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wells Fargo & Company upped their price objective on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. UBS Group increased their target price on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. The Goldman Sachs Group raised their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Finally, TD Cowen boosted their price objective on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $331.73.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $0.11 during trading hours on Friday, hitting $327.68. 702,167 shares of the company traded hands, compared to its average volume of 480,853. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $343.98. The stock has a market capitalization of $14.58 billion, a price-to-earnings ratio of 15.49, a P/E/G ratio of 1.06 and a beta of 0.55. The company has a current ratio of 4.35, a quick ratio of 3.64 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average of $308.33 and a 200 day moving average of $261.26.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period last year, the business posted $5.24 EPS. On average, analysts forecast that United Therapeutics Co. will post 25.59 EPS for the current year.

Insider Activity at United Therapeutics

In related news, Director Christopher Causey sold 2,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $281.53, for a total value of $563,060.00. Following the sale, the director now directly owns 4,185 shares in the company, valued at approximately $1,178,203.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $264.22, for a total transaction of $951,192.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $34,348.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 2,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $281.53, for a total transaction of $563,060.00. Following the completion of the transaction, the director now directly owns 4,185 shares of the company’s stock, valued at $1,178,203.05. The disclosure for this sale can be found here. Insiders have sold 98,644 shares of company stock worth $29,697,857 in the last ninety days. Company insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.